Understanding Refractory Epilepsy: Causes, Symptoms, and Treatment

Refractory epilepsy — also called drug-resistant epilepsy — is epilepsy in which seizures continue despite adequate trials of at least two appropriately chosen antiseizure medications (ASMs). By the International League Against Epilepsy (ILAE) consensus definition, “adequate” means two tolerated and correctly used ASM regimens, whether as monotherapy or in combination. Roughly 30–40% of people with epilepsy meet this definition, making drug resistance one of the most significant challenges in neurology.

This guide covers the causes of refractory epilepsy, how it differs from treatment-responsive epilepsy, current treatment options — including vagus nerve stimulation and other neuromodulation approaches — and the emerging role of genetic testing and precision medicine.

Causes and Risk Factors

Drug resistance in epilepsy is not caused by a single factor. It arises from a combination of biological, structural, and genetic variables that make seizure networks harder to control with medication alone.

Structural Brain Abnormalities

Cortical dysplasia, hippocampal sclerosis, brain tumors, vascular malformations, and damage from prior stroke or traumatic brain injury can all create epileptogenic foci that are inherently resistant to medication. In many of these cases, the seizure-generating tissue has abnormal circuitry that ASMs cannot adequately suppress.

Genetic Factors

Certain genetic epilepsy syndromes carry a high probability of drug resistance. Dravet syndrome (caused by SCN1A mutations), Lennox-Gastaut syndrome, and tuberous sclerosis complex (TSC1/TSC2 mutations) are among the best-characterized examples. Genetic variants can also affect drug metabolism — for instance, CYP2C9 polymorphisms influence how some ASMs are processed — or alter the drug targets themselves, such as sodium channel mutations that reduce ASM binding affinity.

Network and Transporter Mechanisms

Research has identified two key biological hypotheses for drug resistance. The transporter hypothesis proposes that overexpression of efflux transporters (such as P-glycoprotein) at the blood-brain barrier actively pumps ASMs out of the brain before they can reach therapeutic concentrations. The target hypothesis suggests that the molecular targets of ASMs — ion channels and neurotransmitter receptors — undergo structural changes in chronic epilepsy, reducing drug effectiveness.

Other Contributing Factors

Epilepsy with an early age of onset, high initial seizure frequency, a history of status epilepticus, and certain seizure types (particularly tonic and atonic seizures) are all associated with a higher likelihood of drug resistance. Poor medication adherence and drug interactions can also contribute, though these are modifiable factors that should be addressed before a diagnosis of true refractoriness is made.

Refractory Epilepsy in Children vs. Adults

Drug-resistant epilepsy presents differently across age groups, and the distinction matters for treatment planning.

In children, refractory epilepsy is more commonly linked to developmental and genetic epilepsy syndromes such as Dravet syndrome, Lennox-Gastaut syndrome, and infantile spasms (West syndrome). Uncontrolled seizures during critical developmental windows can impair cognitive development, language acquisition, and social skills, making early intervention especially important. Dietary therapies such as the ketogenic diet tend to be better tolerated and more effective in pediatric populations.

In adults, drug-resistant epilepsy more often involves focal epilepsies arising from structural lesions — temporal lobe epilepsy with hippocampal sclerosis is the most common surgically treatable form. Cognitive effects in adults tend to be cumulative, with long-duration uncontrolled seizures contributing to progressive memory and executive function difficulties. Adults are more likely to be candidates for surgical resection or device-based neuromodulation.

Your local vagus nerve experts

Find a vagus nerve practitioner near you

Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.

Or browse by approach

The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.

Diagnosis and Evaluation

Accurately diagnosing refractory epilepsy requires confirming that the epilepsy diagnosis itself is correct (an estimated 20–30% of patients referred to epilepsy centers for drug resistance turn out to have non-epileptic events), that the chosen ASMs were appropriate for the seizure type, and that adequate doses were reached with confirmed adherence.

A comprehensive evaluation at a specialized epilepsy center typically includes:

Video-EEG monitoring — to capture and classify seizure types and localize the epileptogenic zone
High-resolution MRI — to identify structural abnormalities such as cortical dysplasia, tumors, or hippocampal sclerosis
PET and SPECT imaging — to map areas of abnormal brain metabolism or blood flow associated with seizure foci
Neuropsychological testing — to establish cognitive baselines and assess functional impact
Genetic testing — increasingly recommended as a first-tier investigation, with whole-exome or whole-genome sequencing yielding a diagnostic result in roughly 20–40% of patients with unexplained epilepsy. Identifying a genetic cause can directly change treatment: for example, everolimus for TSC-related seizures, or avoidance of sodium channel blockers in Dravet syndrome

Treatment Options

When two or more ASMs have failed to achieve seizure control, the treatment strategy shifts toward a broader toolkit that includes medication optimization, neuromodulation, surgery, dietary therapy, and emerging precision approaches.

Medication Optimization

Even after meeting the ILAE definition of drug resistance, additional ASM trials can still help some patients. Rational polytherapy — combining drugs with complementary mechanisms of action — is a standard approach.

Cenobamate has emerged as one of the most significant additions to the ASM arsenal for focal epilepsy. A 2025 multicenter real-world study of 298 patients with highly refractory epilepsy (median 9 prior failed ASMs) found that 49% achieved at least a 50% seizure reduction at three months, with 14% becoming seizure-free. A pooled analysis published in JAMA found cenobamate outperformed brivaracetam, lacosamide, and perampanel as adjunctive therapy in drug-resistant focal epilepsy.

Fenfluramine (Fintepla) is FDA-approved for seizures associated with both Dravet syndrome and Lennox-Gastaut syndrome. In the phase 3 LGS trial, the higher dose reduced monthly drop seizures by a median of 24% compared to 9% with placebo, with about a quarter of patients achieving at least a 50% reduction.

Other commonly used ASMs in refractory epilepsy include levetiracetam, lamotrigine, topiramate, zonisamide, clobazam, and perampanel, each with different mechanisms and side-effect profiles. Selection should be individualized based on seizure type, syndrome, comorbidities, and pharmacogenomic considerations.

Vagus Nerve Stimulation (VNS)

Vagus nerve stimulation has been FDA-approved for drug-resistant epilepsy since 1997 and remains one of the most established neuromodulation therapies. A pulse generator implanted in the chest delivers regular electrical impulses to the left vagus nerve, which modulates brain activity through widespread neural pathways. VNS does not require identification of a discrete seizure focus, making it suitable for patients who are not candidates for resective surgery.

The CORE-VNS study — a real-world study of over 800 patients across 61 sites — reported a median 74% reduction in generalized tonic-clonic seizures at 12 months and 77% at 24 months, with 43% of patients achieving complete freedom from tonic-clonic seizures at two years. Efficacy tends to improve over time, which is a distinctive feature of VNS compared to most pharmacological treatments.

Side effects are generally mild and include hoarseness during stimulation, cough, and throat discomfort. The procedure is outpatient, does not penetrate the skull, and is approved for patients as young as four years old.

Responsive Neurostimulation (RNS)

The NeuroPace RNS System is a closed-loop device implanted in the skull that continuously monitors brain electrical activity and delivers targeted stimulation when it detects abnormal patterns that could lead to a seizure. Unlike VNS, which delivers stimulation on a fixed schedule, RNS responds in real time to the patient’s own brain signals.

Long-term data show a median seizure reduction of approximately 75% at nine years, with continued improvement over time. RNS is FDA-approved for adults with focal epilepsy arising from one or two seizure foci. The recorded brain data also provides valuable diagnostic information that can guide further treatment decisions.

Epilepsy Surgery

For patients with a clearly identified seizure focus, surgical resection remains the most effective treatment for drug-resistant epilepsy, with seizure-freedom rates of 60–80% for temporal lobe resections. Despite this, epilepsy surgery remains underutilized — the median time from epilepsy onset to surgery exceeds 20 years in many centers.

Laser interstitial thermal therapy (LITT) has become an increasingly popular minimally invasive alternative to open surgery, particularly for mesial temporal lobe epilepsy. LITT uses MRI-guided laser fiber to ablate the epileptogenic focus through a small burr hole. While seizure-freedom rates are somewhat lower than open resection (approximately 50–60% at two years for mesial temporal cases), LITT offers shorter hospital stays, less cognitive risk, and faster recovery. Five-year outcome data presented at the American Epilepsy Society show durable seizure control in a majority of responders.

Dietary Therapy

The ketogenic diet — a high-fat, very-low-carbohydrate diet that shifts the body’s primary fuel source from glucose to ketones — has level-one evidence for reducing seizures in drug-resistant epilepsy. Approximately 50% of patients who adhere to the diet achieve at least a 50% seizure reduction, with 10–15% becoming seizure-free. The modified Atkins diet and low-glycemic-index treatment are less restrictive alternatives with similar efficacy profiles.

The ketogenic diet is the first-line treatment for GLUT1 deficiency syndrome (caused by SLC2A1 mutations), where impaired brain glucose transport makes ketones an essential alternative fuel. It is also increasingly used as a bridge therapy while other interventions are being planned.

Emerging and Precision Therapies

Precision medicine is beginning to transform the treatment of genetic epilepsies. Whole-exome or genome sequencing now changes clinical management in roughly half of tested patients, either by identifying a targeted treatment or by ruling out ineffective ones.

Several gene-targeted therapies are in development:

Zorevunersen, an antisense oligonucleotide for Dravet syndrome, is the most advanced RNA-based epilepsy candidate, with seizure reductions reported in early clinical studies
Everolimus, an mTOR inhibitor, is FDA-approved as adjunctive treatment for refractory focal seizures in tuberous sclerosis patients aged two and older
Preclinical antisense oligonucleotide programs targeting SCN2A, SCN8A, and KCNA2 mutations are underway

Pharmacogenomic screening is also gaining traction — HLA-B*15:02 testing before prescribing carbamazepine reduces the risk of severe skin reactions, and machine-learning tools are improving the reclassification of genetic variants of uncertain significance.

Living with Refractory Epilepsy

Drug-resistant epilepsy affects far more than seizure frequency. Cognitive difficulties, mood disorders (depression and anxiety are two to three times more common in people with epilepsy), medication side effects, driving restrictions, and employment challenges all contribute to a reduced quality of life.

Effective management requires a multidisciplinary team — neurologist, epileptologist, neuropsychologist, social worker, and often a mental health professional. Key strategies include:

Regular seizure tracking to identify patterns and triggers
Screening and treatment for comorbid depression and anxiety
Safety planning, including seizure first-aid education for family and caregivers, and awareness of SUDEP (sudden unexpected death in epilepsy) risk
Cognitive rehabilitation and vocational support
Referral to a comprehensive epilepsy center if not already under specialist care — surgery evaluation should not be delayed

Support organizations such as the Epilepsy Foundation offer resources, peer support, and advocacy for people living with drug-resistant epilepsy.

Ready to dive deeper into the fascinating world of the vagus nerve and unlock even more secrets to your well-being? Discover the comprehensive guide in the “My Vagus Nerve & Me Book,” where you’ll explore the intricate details of this remarkable system. Learn how to naturally and artificially stimulate your vagus nerve, and gain insights into its crucial role in your immune system, digestion, heart rate, and mental health. Embrace the journey to enhanced well-being. Get My Vagus Nerve & Me eBook today and take the first step towards harnessing the power of your body’s most astonishing nerve.